[Click eStock] "Deepnoid, Focus on Expanding Medical AI Business in the Second Half"

Hana Securities forecasted on the 11th that Deepnoid's sales will increase and medical artificial intelligence (AI) orders will grow due to DeepNeuro.

Researcher Jo Jeong-hyun of Hana Securities explained, "The performance growth trend can be confirmed depending on the results of the medical AI business in the second half of this year," and added, "We expect sales to increase as the number of hospitals applying the non-reimbursed brain aneurysm screening solution 'DeepNeuro (DEEP:NEURO)' expands."

He continued, "The number of hospitals adopting DeepNeuro steadily increased to 24 as of the end of last month," and "The goal is to introduce it to 80 hospitals within this year." He also expressed expectations that "entry into domestic health screening centers, a major growth factor for next year, will be possible in the second half of the year."

Researcher Jo analyzed, "Health screening centers have significantly higher numbers of radiology examinations such as CT, MRI, and MRA compared to tertiary general hospitals," and "Since quick screening results are important, the demand for medical AI solution adoption is high." He added, "By signing an MOU with liquid biopsy company Jincast, we aim to supply AI imaging diagnosis and liquid biopsy ctDNA diagnostic package solutions to large screening centers next year," advising, "It is time to pay attention to the growth of the medical AI business."

This content was produced with the assistance of AI translation services.